Latest Regulatory News

Envirosuite Limited shareholders are invited to vote on a $132.2 million acquisition proposal by Ideagen EVS BidCo Pty Limited, with the Envirosuite Board unanimously recommending approval. The scheme offers a significant premium to recent trading prices and is supported by an independent expert report deeming it fair and reasonable.

Elanor Investors Group updates on its ongoing asset divestment program, debt covenant negotiations, and corporate governance reforms as it navigates balance sheet challenges and strategic options.

GR Engineering Services Limited has announced the launch of a Dividend Reinvestment Plan (DRP) starting with its FY25 final dividend, offering shareholders a cost-free way to reinvest dividends into additional shares.

The Reject Shop Limited has received Federal Court approval for its Scheme, enabling a fully franked special dividend of AUD 0.77 per share payable mid-July.

The Federal Court has approved Dollarama’s acquisition of The Reject Shop, triggering a suspension of TRS shares on the ASX and setting the stage for upcoming cash payments to shareholders.

Staude Capital Global Value Fund Limited (GVF) has responded to ASX concerns over a media article revealing details of its capital raising before official announcement, denying any direct media disclosures and reaffirming its compliance policies.

Trigg Minerals Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant capital raise, signaling potential shifts in its financial strategy.

Magmatic Resources has completed the first stage of acquiring the Weebo Gold Project in Western Australia, securing key exploration licenses and gearing up for immediate drilling programs.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Findi Limited’s shares have been suspended from trading on the ASX starting 1 July 2025 due to failure to lodge a required periodic report on time. The suspension will remain until the report is submitted and trading can resume.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Orpheus Uranium has launched a targeted exploration program at its Mt Douglas Project in the Northern Territory, supported by a government co-funding grant and approved permits enabling advanced drilling activities.